Long term outcome and elasticity of a polyester mesh used for laparoscopic ventral hernia repair

por O’Dwyer, P. J., Chew, C., Qandeel, H.
Publicado 2021

Subcutaneous and visceral adipose tissue in patients with primary and recurrent incisional hernia

por Qandeel, H., Chew, C., Young, D., O’Dwyer, P. J.
Publicado 2021

Radiology teaching improves Anatomy scores for medical students

por Chew, C, O’Dwyer, P J, Young, David, Gracie, J A
Publicado 2020

Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days

por Bilenker, J H, Stevenson, J P, Gallagher, M L, Vaughn, D, Cohen, M B, O'Dwyer, P J
Publicado 2004

In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo

por Yao, K, Gietema, J A, Shida, S, Selvakumaran, M, Fonrose, X, Haas, N B, Testa, J, O'Dwyer, P J
Publicado 2005

Phase I/pharmacokinetic/biochemical study of the nitroimadazole hypoxic cell sensitiser SR2508 (etanidazole) in combination with cyclophosphamide.

por O'Dwyer, P. J., LaCreta, F. P., Walczak, J., Cox, T., Litwin, S., Hoffman, J. P., Zimny, M., Comis, R. L.
Publicado 1993

A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer

por Veronese, M L, Sun, W, Giantonio, B, Berlin, J, Shults, J, Davis, L, Haller, D G, O'Dwyer, P J
Publicado 2005

Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells

por Roberts, D, Schick, J, Conway, S, Biade, S, Laub, P B, Stevenson, J P, Hamilton, T C, O'Dwyer, P J, Johnson, S W
Publicado 2005

Gene expression profiling of human ovarian tumours

por Biade, S, Marinucci, M, Schick, J, Roberts, D, Workman, G, Sage, E H, O'Dwyer, P J, LiVolsi, V A, Johnson, S W
Publicado 2006

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

por Schwartz, G K, LoRusso, P M, Dickson, M A, Randolph, S S, Shaik, M N, Wilner, K D, Courtney, R, O'Dwyer, P J
Publicado 2011

MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF(wt) metastatic colorec...

por Tabernero, J., Grothey, A., Arnold, D., de Gramont, A., Ducreux, M., O’Dwyer, P., Tahiri, A., Gilberg, F., Irahara, N., Schmoll, H.-J., Van Cutsem, E.
Publicado 2022

A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.

por Paz-Ares, L., Kunka, R., DeMaria, D., Cassidy, J., Alden, M., Beranek, P., Kaye, S., Littlefield, D., Reilly, D., Depee, S., Wissel, P., Twelves, C., O'Dwyer, P.
Publicado 1998

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

por Eisen, T, Ahmad, T, Flaherty, K T, Gore, M, Kaye, S, Marais, R, Gibbens, I, Hackett, S, James, M, Schuchter, L M, Nathanson, K L, Xia, C, Simantov, R, Schwartz, B, Poulin-Costello, M, O'Dwyer, P J, Ratain, M J
Publicado 2006

Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from...

por Jhaveri, K.L., Wang, X.V., Makker, V., Luoh, S.-W., Mitchell, E.P., Zwiebel, J.A., Sharon, E., Gray, R.J., Li, S., McShane, L.M., Rubinstein, L.V., Patton, D., Williams, P.M., Hamilton, S.R., Conley, B.A., Arteaga, C.L., Harris, L.N., O’Dwyer, P.J., Chen, A.P., Flaherty, K.T.
Publicado 2021

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial

por Mansfield, A. S., Wei, Z., Mehra, R., Shaw, A. T., Lieu, C. H., Forde, P. M., Drilon, A. E., Mitchell, E. P., Wright, J. J., Takebe, N., Sharon, E., Hovelson, D., Tomlins, S., Zeng, J., Poorman, K., Malik, N., Gray, R. J., Li, S., McShane, L. M., Rubinstein, L. V., Patton, D., Williams, P. M., Hamilton, S. R., Conley, B. A., Arteaga, C. L., Harris, L. N., O’Dwyer, P. J., Chen, A. P., Flaherty, K. T.
Publicado 2022